TELUS Reports Third Quarter 2026 Results, Demonstrates Continued Discipline in Core Telecom; Advances Transformation Strategy

TELUS reported a C$660 million Q3 net loss, including a non-cash C$800 million TELUS Health goodwill impairment; adjusted net income fell 32% to C$251 million and adjusted EBITDA declined 5% to C$1.76 billion. Free cash flow fell 35% to C$396 million, while net debt leverage was 3.6x; the company reaffirmed 2026 guidance and is targeting C$900 million in annualized cash savings exiting 2028 to support deleveraging. TELUS is prioritizing monetization of TELUS Health and TELUS Agriculture & Consumer Goods and plans investments in Canadian telecom and AI infrastructure.

Analysis

The key question is conversion, not the announced savings headline. TELUS has raised its 2026 restructuring-cost assumption to C$900 million, including about C$650 million of cash disbursements, while targeting C$900 million of annualized savings only by year-end 2028. This creates a multi-year cash-flow bridge risk: execution costs and elevated network investment can absorb savings before they reach free cash flow. Track realized run-rate savings, cash restructuring outlays, and capex—not adjusted EBITDA alone.

Asset sales are similarly leverage-sensitive. Selling Health or Agriculture and directing proceeds to debt can lower debt, but also removes EBITDA; the leverage ratio improves only if proceeds relative to divested earnings are attractive and the remaining telecom business holds up. The Health impairment raises the risk that transaction pricing disappoints versus carrying value, while the buyer pool and sale perimeter remain unverified. TELUS Digital’s hyperscale-client exposure is a separate structural headwind: automation can erode legacy volumes faster than AI-related services replace them.

Near term, low mobile churn and stable ARPU support the floor, but modest network growth does not yet underwrite a broad earnings re-rating. Over 1–3 months, watch asset-sale terms, cash restructuring spend, and management’s quantified savings cadence. Over 6–18 months, execution against capex and debt reduction matters more than the non-cash impairment. PureFibre and partner-led data-centre connectivity offer upside, but sovereign-AI demand is not yet evidence of attractive returns; avoid capitalizing it ahead of contracts and returns disclosure. TELUS’s disclosed AST SpaceMobile integration risk is not a new catalyst in this release.

Key Decisions for Investors

• Keep TELUS common shares underweight versus Canadian telecom peers until quarterly disclosures demonstrate cash savings and FCF conversion; reassess if adjusted EBITDA stabilizes without a renewed capex or cash-restructuring overshoot.
• Prefer monitoring TELUS credit over buying the equity for a deleveraging thesis. Consider relative-value exposure only if bond spreads compensate for execution risk; verify current spreads, maturities, and covenant treatment before entry.
• Treat Health and Agriculture monetization as a catalyst, not a base-case debt-reduction input. Reassess when TELUS discloses sale scope, proceeds, retained earnings, and use of proceeds; weak multiples or a material EBITDA reduction would undermine the 3.0x leverage path.
• Falsifiers: sustained mobile ARPU/churn deterioration, repeated guidance cuts, or cash restructuring outlays and capex that prevent FCF growth would reinforce caution; documented savings run-rate, attractive asset-sale proceeds relative to EBITDA sold, and declining net leverage would support reducing the underweight.